Coverage
ADCs & Radiopharma
ADCs & Radiopharma
ADCs & Radiopharma
ADCs & Radiopharma
ADCs & Radiopharma
ADCs & Radiopharma
ADCs & Radiopharma
ADCs & Radiopharma
ADCs & Radiopharma coverage from APO|APE News.
European Commission Approves Gilead's Trop-2 ADC Trodelvy Plus Keytruda for First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Radiopharm Theranostics Clears Safety Review to Open 180 mCi Cohort in 177Lu-RAD202 HER2 Radioligand Trial
Enhertu Improves Progression-Free Survival Over Pembrolizumab Plus Chemotherapy in First-Line HER2-Mutant NSCLC in DESTINY-Lung04
Biokin's EGFRxHER3 Bispecific ADC Iza-bren Meets PFS Endpoint in China Phase 3 in EGFR-Mutant NSCLC
Five Australian Clinicians Set Out When to Escalate, Pause and Restart 177Lu-PSMA Rather Than Run Six Fixed Cycles
Dimeric FAP Radioligand 177Lu-D7ND Reaches Its First Five Patients After Complete Remissions in Xenografts